{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:16:38Z","timestamp":1790396198970,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clbc.2017.10.013","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T14:30:32Z","timestamp":1508855432000},"page":"88-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A\u00a0Multicenter Phase II Trial by the Hellenic Oncology Research Group"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-0120","authenticated-orcid":false,"given":"Emmanouil","family":"Saloustros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kalbakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Christofillakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6037-5707","authenticated-orcid":false,"given":"Nikolaos","family":"Kentepozidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Pistamaltzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Kourousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lampros","family":"Vamvakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2017.10.013_bib1","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(11)61351-2","article-title":"Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis","volume":"378","author":"Forouzanfar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2017.10.013_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMra0801289","article-title":"Gene-expression signatures in breast cancer","volume":"360","author":"Sotiriou","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2017.10.013_bib3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2017.10.013_bib4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2017.10.013_bib5","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2017.10.013_bib6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A\u00a0gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2017.10.013_bib7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2017.10.013_bib8","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ejca.2008.07.019","article-title":"Chemotherapy in metastatic breast cancer: a summary of all randomised trials reported 2000-2007","volume":"44","author":"Wilcken","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2017.10.013_bib9","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1200\/JCO.2002.08.129","article-title":"Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer","volume":"20","author":"Loesch","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.013_bib10","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1158\/1078-0432.CCR-03-0133","article-title":"Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer","volume":"10","author":"Estevez","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2017.10.013_bib11","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1200\/JCO.2008.21.4163","article-title":"Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study","volume":"27","author":"Sikov","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.013_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdq041","article-title":"Weekly paclitaxel plus carboplatin is an effective non\u2013 anthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer","volume":"21","author":"Chen","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2017.10.013_bib13","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdp062","article-title":"Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple negative breast cancer","volume":"20","author":"Linderholm","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2017.10.013_bib14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000336892","article-title":"First-line bevacizumab containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study","volume":"82","author":"Thomsses","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.clbc.2017.10.013_bib15","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2017.10.013_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2017.10.013_bib17","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2017.10.013_bib18","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1038\/bjc.2014.504","article-title":"Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses","volume":"111","author":"Brodowicz","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2017.10.013_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CE.S52197","article-title":"Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis","volume":"9","author":"Clark","year":"2014","journal-title":"Core Evid"},{"key":"10.1016\/j.clbc.2017.10.013_bib20","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/cncr.30170","article-title":"Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: results from the GINECO A-TaXel phase 2 study","volume":"122","author":"Ferrero","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2017.10.013_bib21","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O\u2019Shaughnessy","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.013_bib22","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S1470-2045(16)30154-1","article-title":"Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial","volume":"17","author":"Zielinski","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2017.10.013_bib23","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1158\/1078-0432.CCR-08-1208","article-title":"Triple-negative breast cancer: risk factors to potential targets","volume":"14","author":"Schneider","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9 supplement","key":"10.1016\/j.clbc.2017.10.013_bib24","article-title":"The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1\/2 breast cancer (CRUK\/07\/012) (abstract S3-01)","volume":"75","author":"Tutt","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2017.10.013_bib25","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","article-title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","volume":"14","author":"Cameron","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5 suppl","key":"10.1016\/j.clbc.2017.10.013_bib26","article-title":"Bevacizumab in the adjuvant treatment of HER2 negative breast cancer: final results from Eastern Cooperative Oncology Group E5103 (abstract 500)","volume":"32","author":"Miller","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4 supplement","key":"10.1016\/j.clbc.2017.10.013_bib27","article-title":"Nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine\/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: results from the randomized phase 2 portion of the TnAcity trial (abstract P5-15-03)","volume":"77","author":"Yardley","year":"2017","journal-title":"Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820917301532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820917301532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:17:13Z","timestamp":1761513433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820917301532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1526820917301532"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2017.10.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A\u00a0Multicenter Phase II Trial by the Hellenic Oncology Research Group","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2017.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}